EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis

Lara Boucher, Nathalie Sorel, Christophe Desterke iD, Mélanie Chollet, Laura Rozalska, Maria Pilar Gallego Hernanz, Emilie Cayssials, Anna Raimbault iD, Annelise Bennaceur-Griscelli iD, Ali G Turhan iD, Jean-Claude Chomel iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242015441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lara Boucher und 10 weiteren Autor:innen. Beteiligte Einrichtung: CHU de Poitiers, Service de Cancérologie Biologique, F86000 Poitiers, France. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML patients. Two AML patients harboring a BCR::ABL1 fusion were included in the study. We identified BCR::ABL1 fusion as a primary event in one patient and a secondary one in the other. AML-specific variants were identified in both. Real-time RT-PCR experiments demonstrated that CD25 mRNA is overexpressed in advanced-phase CML compared to AML. Unsupervised principal component analysis showed that AML harboring a BCR::ABL1 fusion was clustered within AML. An AML vs. myeloid BC-CML differential expression signature was highlighted, and while ID4 (inhibitor of DNA binding 4) mRNA appears undetectable in most myeloid BC-CML samples, low levels are detected in AML samples. Therefore, CD25 and ID4 mRNA expression might differentiate AML with BCR::ABL1 from BC-CML and assign it to the AML group. A method for identifying this new WHO entity is then proposed. Finally, the hypothesis of AML with BCR::ABL1 arising from driver mutations on a BCR::ABL1 background behaving as a clonal hematopoiesis mutation is discussed. Validation of our data in larger cohorts and basic research are needed to better understand the molecular and cellular aspects of AML with a BCR::ABL1 entity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteHumansBlast CrisisFusion Proteins, bcr-ablRetrospective StudiesRNA, Messenger

Stichwörter der Autor:innen

AMLAML with BCR::ABL1CD25CMLID4RNA-Seq

Substanzen

Fusion Proteins, bcr-ablRNA, Messenger

Autor:innen und Institutionen

  • CHU de Poitiers, Service de Cancérologie Biologique, F86000 Poitiers, France.
  • Faculté de Médecine, Université Paris Saclay, F94270 Le Kremlin-Bicêtre, France.
  • CHU de Poitiers, Service d'Hématologie Biologique, F86000 Poitiers, France.
  • CHU de Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, F86000 Poitiers, France.
  • INSERM, CIC-P 1402, F86000 Poitiers, France.
  • INSERM U1310, F94807 Villejuif, France.

ORCID-Profile: Christophe Desterke, Anna Raimbault, Annelise Bennaceur-Griscelli, Ali G Turhan, Jean-Claude Chomel

Zitieren

APA

Boucher, L., Sorel, N., Desterke, C., Chollet, M., Rozalska, L., Gallego Hernanz, M. P., Cayssials, E., Raimbault, A., Bennaceur-Griscelli, A., Turhan, A. G., & Chomel, J. C. (2023). Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015441

Vancouver

Boucher L, Sorel N, Desterke C, Chollet M, Rozalska L, Gallego Hernanz MP, et al. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015441

BibTeX
@article{Boucher2023,
  author = {Boucher, Lara and Sorel, Nathalie and Desterke, Christophe and Chollet, Mélanie and Rozalska, Laura and Gallego Hernanz, Maria Pilar and Cayssials, Emilie and Raimbault, Anna and Bennaceur-Griscelli, Annelise and Turhan, Ali G and Chomel, Jean-Claude},
  title = {Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242015441}
}
Kostenlos starten →